Reviewer's report

Title: Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation

Version: 1 Date: 13 October 2008

Reviewer: Shlomo Melmed

Reviewer's report:

This is a comprehensive and well documented Review.

1. Figure 4. These survival curves do not take into account the toxic effects of the drug--including longterm liver abnormalities which will impact morbidity longterm, as well as cost. Furthermore what is missing is a curve depicting alternate therapies--eg surgery or somatostatin analog which will likely yield a more favorable curve,given the side effects of PEG.

2. Please address side effects more comprehensively eg the lipohypertrophy caused by the drug. See Bonert et al in JCEM 2008.Also, the hepatitis question requires far more critical analysis,as well as the potential for continued (or accelerated??) tumor growth in the longterm. This leaves a poor balance to the review which is otherwise excellent.